Sepsis is a severe life-threatening infection with organ dysfunction that triggers a complex interplay between host pro-inflammatory and anti-inflammatory processes. It is a race between pathogens and the host immune system, with the balance of pro- and anti-inflammatory pathways determining survival. Despite many failed clinical trials, understanding the pathophysiology of sepsis and its associated immune responses offers new treatment approaches. Biomarker-guided immunotherapy during the appropriate immune phase of sepsis could be a major advancement in sepsis treatment. Sepsis is defined as the host's inflammatory response to severe infection with organ dysfunction. It is the most common cause of mortality in intensive care units and causes over 250,000 deaths annually in the US. The incidence of sepsis is increasing due to an aging population with impaired immunity. Recent studies suggest that both pro-inflammatory and anti-inflammatory responses occur early and simultaneously in sepsis, though the initial phase is typically hyperinflammatory. The immune response in sepsis is debated, with two main theories: one suggesting a hyperinflammatory phase followed by immunosuppression, and another proposing persistent innate immune activation leading to inflammation and organ injury. Sepsis induces immunosuppression through various mechanisms, including apoptosis of immune cells, reduced cytokine production, and increased expression of inhibitory receptors. Immunosuppression is a major driver of morbidity and mortality in sepsis, with post-mortem studies showing marked immunosuppression in septic patients. The failure of many clinical trials of anti-inflammatory agents is inconsistent with the hypothesis that inflammation is a key driver. However, focal inflammation in infected tissue may contribute to organ dysfunction in some patients. Sepsis-induced apoptosis of immune cells, including CD4+ and CD8+ T cells, B cells, and dendritic cells, leads to immunosuppression. This apoptosis occurs through death receptor- and mitochondrial-mediated pathways. Preventing lymphocyte apoptosis improves survival in sepsis. Sepsis also impairs the function of neutrophils, monocytes, macrophages, and dendritic cells, leading to reduced bacterial clearance and increased susceptibility to secondary infections. Immunotherapies such as recombinant IL-7 and PD1/PDL1-specific antibodies show promise in reversing immunosuppression in sepsis. IL-7 improves T cell function, increases T cell receptor diversity, and enhances T cell trafficking. PD1/PDL1-specific antibodies prevent T cell exhaustion and improve survival in sepsis models. These therapies target the adaptive immune system and may be effective in restoring immune function in sepsis. The role of immunosuppressive cells like regulatory T cells and myeloid-derived suppressor cells is also significant in sepsis. Understanding these mechanisms is crucial for developing effective immunotherapies for sepsis.Sepsis is a severe life-threatening infection with organ dysfunction that triggers a complex interplay between host pro-inflammatory and anti-inflammatory processes. It is a race between pathogens and the host immune system, with the balance of pro- and anti-inflammatory pathways determining survival. Despite many failed clinical trials, understanding the pathophysiology of sepsis and its associated immune responses offers new treatment approaches. Biomarker-guided immunotherapy during the appropriate immune phase of sepsis could be a major advancement in sepsis treatment. Sepsis is defined as the host's inflammatory response to severe infection with organ dysfunction. It is the most common cause of mortality in intensive care units and causes over 250,000 deaths annually in the US. The incidence of sepsis is increasing due to an aging population with impaired immunity. Recent studies suggest that both pro-inflammatory and anti-inflammatory responses occur early and simultaneously in sepsis, though the initial phase is typically hyperinflammatory. The immune response in sepsis is debated, with two main theories: one suggesting a hyperinflammatory phase followed by immunosuppression, and another proposing persistent innate immune activation leading to inflammation and organ injury. Sepsis induces immunosuppression through various mechanisms, including apoptosis of immune cells, reduced cytokine production, and increased expression of inhibitory receptors. Immunosuppression is a major driver of morbidity and mortality in sepsis, with post-mortem studies showing marked immunosuppression in septic patients. The failure of many clinical trials of anti-inflammatory agents is inconsistent with the hypothesis that inflammation is a key driver. However, focal inflammation in infected tissue may contribute to organ dysfunction in some patients. Sepsis-induced apoptosis of immune cells, including CD4+ and CD8+ T cells, B cells, and dendritic cells, leads to immunosuppression. This apoptosis occurs through death receptor- and mitochondrial-mediated pathways. Preventing lymphocyte apoptosis improves survival in sepsis. Sepsis also impairs the function of neutrophils, monocytes, macrophages, and dendritic cells, leading to reduced bacterial clearance and increased susceptibility to secondary infections. Immunotherapies such as recombinant IL-7 and PD1/PDL1-specific antibodies show promise in reversing immunosuppression in sepsis. IL-7 improves T cell function, increases T cell receptor diversity, and enhances T cell trafficking. PD1/PDL1-specific antibodies prevent T cell exhaustion and improve survival in sepsis models. These therapies target the adaptive immune system and may be effective in restoring immune function in sepsis. The role of immunosuppressive cells like regulatory T cells and myeloid-derived suppressor cells is also significant in sepsis. Understanding these mechanisms is crucial for developing effective immunotherapies for sepsis.